The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial-Reference-Cited by-同舟云学术

The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial

Published:2021-12 Issue: Volume: Page:
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Verdonschot Job A.J.^ORCID,Ferreira JoÃo Pedro,Pizard Anne,Pellicori Pierpaolo,Brunner La Rocca Hans-Peter,Clark Andrew L.,Cosmi Franco,Cuthbert Joe,Girerd Nicolas,Waring Olivia J.^ORCID,Henkens Michiel H.T.M.,Mariottoni Beatrice,Petutschnigg Johannes,Rossignol Patrick,Hazebroek Mark R.,Cleland John G.F.,Zannad Faiez,Heymans Stephane R.B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Epidemiology and risk profile of heart failure;Bui;Nat Rev Cardiol,2011

2. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies;Aune;Circulation,2016

3. Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk;Mathieu;Rev Endocrine Metab Disord,2014

4. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial;Olivier;Eur J Heart Fail,2017

5. Associations of body mass index with laboratory and biomarkers in patients with acute heart failure;Streng;Circ Heart Fail,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the CCL5 and Its Receptor, CCR5, in the Genesis of Aldosterone-Induced Hypertension, Vascular Dysfunction, and End-Organ Damage;Hypertension;2024-04

2. Role Of The C-C Motif Chemokine Ligand 5 (CCL5) And Its Receptor, C-C Motif Chemokine Receptor 5 (CCR5) In The Genesis Of Aldosterone-induced Hypertension, Vascular Dysfunction, And End-organ Damage;2023-09-23

3. Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension;Current Opinion in Cardiology;2023-08-01